drugset / Trial / NCT07011095

DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial

NCT07011095

Phase 0 Not yet recruiting 100 enrolled Population Health Research Institute
RandomizedFactorialOpen-labelTreatment

Summary

People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people. Options include continuing the same DOAC, switching to another DOAC or switching to warfarin. The investigators of the SWITCH-AF trial are trying to find out whether switching to warfarin or continuing a DOAC is better for preventing stroke. The purpose of this study, called a pilot study, is to test the study plan and to find out whether enough participants will join a larger study that answers the question. A pilot study involves a small number of participants and it is not expected to tell us which treatment is better.

Timeline

Start
2025-09-03
Primary completion
2027-02-03
Completion
2027-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule
Subject Dabigatran Unknown
Subject Rivaroxaban Other / unclassified
Subject Warfarin Small molecule

Indications